Proprietary portfolio of superior therapeutics for the treatment of diabetes and obesity
- Two clinical stage next-generation insulin candidates with compelling clinical superiority to best insulins available to patients today
- Positive negotiations with device companies to further develop and commercialise proprietary insulin products
- Novel technology platform for the oral delivery of peptides under development
Partnering with leading pharmaceutical and MedTech companies to develop enhanced therapeutic medicines
- One product now on the market that incorporates Arestat™ and generating royalties under worldwide license agreement
- Two additional products under license for further development and commercialisation
- Near term revenue-generation and significant future upside potential
Validated technology
- World-leading Arestat™ technology platform
- Extensive IP protection with >100 granted patents in US, Europe and key territories